Longtime Apitope CEO Keith Martin steps down; Clearside Biomedical taps Spark exec as CMO
→ Keith Martin is retiring from the CEO post at Apitope, the University of Bristol spinout he’s led from launch to clinical stage. While the biotech searches for a permanent replacement, Hayley French is stepping up to the responsibilities as the newly installed COO. She will likely preside over an eventful time Apitope, with three new trials coming up for its autoimmune therapies in the next quarter. But she has had plenty of time to get familiar with the pipeline in the past eight years, most recently as CBO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
